Dasatinib

製品コードS1021 別名:BMS-354825

Dasatinib化学構造

分子量(MW):488.01

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

サイズ 価格(税別)  
JPY 23240.00
JPY 24402.00
JPY 61420.00

文献中Selleckの製品使用例(73)

カスタマーフィードバック(13)

  • Antitumor activity (A)and body weight (B) relationship for BLU-285 and dasatinib in a P815 KIT D814Y mastocytoma allograft model.

    Science, 2017, 9(414), doi: 10.1126/scitranslmed.aao1690. Dasatinib purchased from Selleck.

    Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.

    Cell Res 2011 21, 1080-1087. Dasatinib purchased from Selleck.

  • Cytotoxicity by Dasatinib and Nutlin-3 used alone or in combination in B-CLL patient leukemic cells. B-CLL patient leukemic cells were exposed to serial doses of Dasatinib or Nutlin- 3 used either alone or in combination, with a fixed ratio, for 48 hours. Dose-effect plots, to determine drug efficacy, are shown for representative B-CLL samples, including 3 patients carrying 17p- (Pt. #7, Pt. #8, and Pt. #10). The decrease of cell viability, labeled "effect" on the Y-axis, was determined in assays done at least twice in duplicate.

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Dasatinib interferes with the p53 transcriptional activity induced by Nutlin-3. Leukemic cell lines were exposed for 24 hours to Dasatinib (10 μM) and Nutlin-3 (10 μM), used either alone or in combination, as indicated. Levels of p53 (A), MDM2 and p21 (B) were assessed by Western blot analysis of total cell lysates. Representative examples of Western blot results are shown. Tubulin staining is shown as loading control; after densitometric analyses, p53 as well as MDM2 and p21 protein levels are expressed as folds of protein modulation, by the indicated treatments, with respect to the control untreated cultures set to 1 (hatched line). *P < 0.05 with respect to the Nutlin-3-treated cultures.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Role of Akt in Dasatinib cytotoxicity and in DasatinibtNutlin-3 synergy. A, whole cell lysates were prepared from EHEB and BJAB cell lines treated (for 16 hours) as indicated, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls (set at 100) on the same membrane. The analysis of modulation of phosphorylation signals for P-ERK1/2, P-p38, and P-Akt are reported (*P < 0.05). Validation of phospho-kinase array results was carried out by Western blot analysis of P-Akt levels.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Impact of the TKI erlotinib, lapatinib, dasatinib, and sorafenib on the viability of MDS/AML cells. MOLM-13 (A) and HL-60 (B) cells were incubated with the indicated doses (given in mM below the x-axis) of the 4 TKI, and cellular viability was assessed by MTT assay after 24, 48 and 72 h of incubation. Changes in viability are given as percentage of cells as compared to non-treated control samples. This experiment was repeated at least three times, yielding comparable results. Graphs show representative results of one experiment carried out in duplicates (mean standard deviation).

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

  • Capacity of the TKI to overcome the AML-typical differentiation blockage. The myeloid cell lines MOLM-13 and HL-60 were incubated for 6 days with 0.01% DMSO (serving as a negative solvent control), 1 μM of ATRA (serving as a positive control), as well as with the indicated doses of the four TKI. (A) Representative May -Gruenwald -Giemsa staining of MOLM-13 cells, (B) quantitation of the percentage of MOLM-13 cells exhibiting at least two morphological signs of differentiation (that is a decrease in cytoplasmic basophilia, a reduction of the nucleo-cytoplasmic ratio, appearance of nuclear lobulation and/or cytoplasmic granules). Percentages were evaluated by examining at least 100 cells/condition; (C) representative FACS overlays of MOLM-13 cells depicting TKI-induced CD11b expression (black line) as compared to the isotype (shaded grey); (D) quantitation of TKI-induced CD11b-expression in MOLM-13 cells; (E) representative slides depicting morphology/staining of MOLM-13 cells assessed in the NBT-reduction assay; (F) respective quantitative assessment demonstrating the NBT-reducing capacity under the different drugs; (G) representative May-Gruenwald-Giemsa staining of HL-60 cells.

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

    Cytotoxicity by Dasatinib treatment in leukemic cells.Leukemic cell lines were exposed to Dasatinib (10 μM). Upon treatment, cell viability (a) was calculated as percentage with respect to the control vehicle cultures (set to 100% for each cell line) and induction of apoptosis (b) was calculated as percentage of Annexin V+/PI+ cells after 48 h of treatment.

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Human phospho-kinase array analysis in response to Dasatinib treatment. Whole cell lysates were prepared from EHEB (p53wt) and BJAB (p53mut) B cell lines, either left untreated or exposed to Dasatinib for 24 h, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls on the same membrane. In a, intense decreases of signal of P-p38, PERK1/2 and P-CREB in response to Dasatinib are indicated by arrows in the membranes, and intensity of corresponding spots are reported as graphics. In b, analysis of modulation of phosphorylation of STAT family members in response to Dasatinib (spots not shown). The means±SD of three independent experiments are shown. Asterisk indicates P<0.05 against untreated.

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

    Cells were either left untreated (Unt.) or exposed to Dasatinib (Das.) for 24 h. Equal amounts of cell lysates were analyzed for ERK1/2, p38 and CREB phosphorylation by Western blot using antibodies specific for the native form of the kinases and for residues that are phosphorylated (P-) in each kinase upon activation. One of three experimentswith similar results is shown. Protein bands were quantified by densitometry and level of PERK1/2, P-p38 and P-CREB expressed as arbitrary units,were calculated for each cell line after normalization to total ERK1/2, p38 and CREB respectively

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Effect of dasatinib on endothelial cell actin fiber organization. Subconfluent human microvascular endothelial cells‐1 were treated with dimethyl sulfoxide (A) or dasatinib (B), fixed, permeabilized and stained with phalloıdin (green) for F‐actin or FAK (red) for adhesion plaques. Images were taken in a confocal microscope (1000X).

    Cancer Med, 2017, 6(4):809-818. Dasatinib purchased from Selleck.

    Inhibition of cell growth upon culturing of primary bone marrow cells from an EMS patient and a healthy control in presence of TKIs in vitro. EMS cells showed reduced cell growth compared to the healthy control cells when cultured with ponatinib, dovitinb or dasatinib. Cell growth was evaluated after 72 hours in culture. All samples were normalized to DMSO controls. Non-linear regression curves were fitted for evaluation of IC50 values. Error bars represent mean values and standard deviation of the analyzed replicates.

    Eur J Haematol, 2017, 99(5):442-448. Dasatinib purchased from Selleck.

  • Cell vability test result. Different cell lines (A2C12, Beta D5, Gamma A3, Gamma D12, A549, CaCo2,Hep G2) were treated with different concentration of Dasatinib.

     

     

    Dr. Thomas Kruwel of Fraunhofer-Institute for Toxicology and Experimental Medicine-Dasatinib (BMS-354825) purchased from Selleck. Dasatinib purchased from Selleck.

製品安全説明書

Src阻害剤の選択性比較

生物活性

製品説明 Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.
ターゲット
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
体外試験

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 MkHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLEO|IhcA>? MXfEUXNQ MWrJR|UxRTBwMECwNFch|ryP MWCxO|k2PjB6MB?=
K562 NFPjWotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUe3NkBp NIjVXnFFVVOR NFTSSYFKSzVyPUCuNFAyKM7:TR?= NHiwNYMyPzl3NkC4NC=>
M07e NUXWb|V5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnvO|IhcA>? NHi0UWRFVVOR NWH3bm9rUUN3ME2wMlAxOTJizszN M{XSVFE4QTV4MEiw
ALL3 NGXJOYdEgXSxdH;4bYMhSXO|YYm= NIPXdmExNjIQvF2= NFHyU2E4OiCq NWfZfXhtTE2VTx?= M3vUNmlEPTB;MD6wNFA1KM7:TR?= M{PWT|E6QDh7NUSw
CML M{DH[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7QV5ozOCCvaX6= NHryV2FFVVOR MlvXTWM2OD1yLkCwNUDPxE1? NGnOUHcyQTJzOUCxOi=>
BA/F3 M2X2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nIWlczKGh? MnPlSG1UVw>? MVzJR|UxRTZwNUi5JO69VQ>? MWqyN|A5QDZ2NB?=
BA/F3 M3\WVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLPclFqPzJiaB?= NXzFXpBKTE2VTx?= MkO5TY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy|IHX4dJJme3OrbnegRoNzNUGkbDDNN|UyXCCvdYThcpQhf2m2aDDJR|UxKG:oIECuNFAxQDQQvF2= MY[yN|A5QDZ2NB?=
BA/F3 Ml76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nYW|czKGh? M{XoOGROW09? M3ju[Glv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO|aX7nJJdqdGRidInw[UBD[3JvQXLsJJdqfGhiSVO1NEBw\iByLkCwOFXPxE1? NWPmd5RsOjNyOEi2OFQ>
BA/F3 NVnXPGxWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrVO2VMPzJiaB?= NUf3ZndLTE2VTx?= NFrCZmRKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW|c3nu[{BD[3JvQXLsJHQ{OTWLIH31eIFvfCC5aYToJGlEPTBib3[gNU44OTUQvF2= MX[yN|A5QDZ2NB?=
BA/F3 M122eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUP3bnJ1PzJiaB?= M3TZcWROW09? MUPJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBHPDh4UzDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECwPe69VQ>? NXL4NZlIOjN|MEG3NFM>
BA/F3 MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFqyNWo4OiCq MmmwSG1UVw>? M3zoTmlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEV{NUXLJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFMz|ryP MoDhNlM{ODF5MEO=
BA/F3 M4ToOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEG1ZZI4OiCq Mo\HSG1UVw>? NHLNU2JKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCJMkWwSUBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFA2Oc7:TR?= MVqyN|MxOTdyMx?=
BA/F3 NFLXSppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoexO|IhcA>? M2TQVmROW09? M3mxNGlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKFF{NULIJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFjPxE1? MmjPNlM{ODF5MEO=
BA/F3 NULGUW1LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnjO|IhcA>? Mm\6SG1UVw>? NFTxS5NKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCHM{W5WkBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFAyO87:TR?= NYXvWZhZOjN|MEG3NFM>
BA/F3 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVS3NkBp MnXVSG1UVw>? NH21XFJKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIFLDVk1CSkxiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECxPe69VQ>? NID3SG4zOzNyMUewNy=>
BA/F3 NYS2Vo5FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHLVJFVPzJiaB?= NEfDbFhFVVOR NH\hOohKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCC\MkWzTEBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFAzO87:TR?= M3nlflI{OzBzN{Cz
BA/F3 NXzoOHU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Pib|czKGh? NFnnTJlFVVOR MYDJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBVOzF3STDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDNwNt88US=> MXKyN|MxOTdyMx?=
BA/F3 M2jpTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDFW3EzPzJiaB?= MlzmSG1UVw>? NVe2ZVE2UW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiSX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOi53zszN MVGyN|MxOTdyMx?=
T cell NIS3SXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHhO|IhcA>? NVPzTmVyTE2VTx?= NUDZbVk{UW6qaXLpeJMh[W62aTDDSFMuKGGwZDDhcpRqKEOGMkitbY5lfWOnZDDUJINmdGxicILvcIln\XKjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFPPxE1? MYKxO|E2PDVzMh?=
WiDr M2fBO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUW3NkBp MlTJSG1UVw>? MXjJR|UxRTBwMEWyJO69VQ>? NUHyVWNiOTV4MUW1NVI>
PC3 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nnZlczKGh? NHLrT|JFVVOR Mlr2TWM2OD1yLkCwPVQh|ryP MoPTNVU3OTV3MUK=
MDA-MB-231 M{DLOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXKO|IhcA>? MVfEUXNQ MkHmTWM2OD1yLkCxNkDPxE1? MX:xOVYyPTVzMh?=
Hs578T NWT0O|hDS3m2b4TvfIlkKEG|c3H5 NH\1ZYE4OiCq M3TsSGROW09? MmT5S2k2OD1yLkCzJO69VQ>? MV:yOFAyPTN{Nx?=
HMEC MYfDfZRwfG:6aXOgRZN{[Xl? MkHXO|IhcA>? NYLvPFM5TE2VTx?= MWfHTVUxRTFwODFOwG0> M13JPFI1ODF3M{K3
DU145 NVnnPJZrS3m2b4TvfIlkKEG|c3H5 NGXIO5o4OiCq MVfEUXNQ NW\ETIdJT0l3ME2wMlE3KM7:TR?= M2jObVI1ODF3M{K3
U251 NEexNZFEgXSxdH;4bYMhSXO|YYm= Ml;NO|IhcA>? NUfPT|lITE2VTx?= MlPjS2k2OD1{LkixJO69VQ>? M2DvUFI1ODF3M{K3
NCI60 NIm3VmhEgXSxdH;4bYMhSXO|YYm= MnjoO|IhcA>? MXfEUXNQ NWXyUmpPT0l3ME21Mlch|ryP MVyyOFAyPTN{Nx?=
MALME-3M NGftdmxEgXSxdH;4bYMhSXO|YYm= MofEO|IhcA>? NX7BbZpSTE2VTx?= M{XadmdKPTB;Nj62NUDPxE1? MWOyOFAyPTN{Nx?=
KM12 NIXYeZhEgXSxdH;4bYMhSXO|YYm= NHvZUGg4OiCq M2H1TWROW09? MmfYS2k2OD15LkS0JO69VQ>? NGT4R3gzPDBzNUOyOy=>
SW620 MVTDfZRwfG:6aXOgRZN{[Xl? MnyyO|IhcA>? MoPWSG1UVw>? M{TSOWdKPTB;OD60N{DPxE1? MkHyNlQxOTV|Mke=
RXF 393NL MWLDfZRwfG:6aXOgRZN{[Xl? M1LhdVQh\GG7cx?= NX2xbG1lTE2VTx?= M4XvcmlEPTB;MD6wNlE4KM7:TR?= NVv4XHFWOjN{NUOwO|Q>
LXFA 983L MmTlR5l1d3SxeHnjJGF{e2G7 NG[zU5g1KGSjeYO= NUjLcWtmTE2VTx?= MljtTWM2OD1yLkC1OlUh|ryP NXjpUok1OjN{NUOwO|Q>
PRXF DU145 NUDsTnVKS3m2b4TvfIlkKEG|c3H5 Mn;BOEBl[Xm| MWjEUXNQ MnKwTWM2OD1yLkC2NlMh|ryP MW[yN|I2OzB5NB?=
PAXF 1657L NEjkR4xEgXSxdH;4bYMhSXO|YYm= Mn7IOEBl[Xm| NUW0coNqTE2VTx?= M{ew[GlEPTB;MD6xNlEh|ryP NWWxVY1WOjN{NUOwO|Q>
CXF 1103L NI\x[GpEgXSxdH;4bYMhSXO|YYm= NVu0Z4VSPCCmYYnz NY[yZZRYTE2VTx?= NXrxfIRTUUN3ME20MlM3KM7:TR?= NHXtbI0zOzJ3M{C3OC=>
GXF251L MmX0R5l1d3SxeHnjJGF{e2G7 MmDtOEBl[Xm| NWfScYtnTE2VTx?= MmryTWM2OD1{LkK1JO69VQ>? NFfReZozOzJ3M{C3OC=>
NCI-H23 M4SySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjJO|IhcA>? NX:zboxFTE2VTx?= MV7JR|UxRTJwMkeg{txO MYKyN|UzOTB{MB?=
HCT116 Mn3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2K1cFczKGh? MnfoSG1UVw>? MWnJR|UxRTJwMzFOwG0> NGT1[3IzOzV{MUCyNC=>
MCF7 M1vSVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;5SFczKGh? NVvTTWhITE2VTx?= NWCyeYNRUUN3ME2yMlU4KM7:TR?= M1exU|I{PTJzMEKw
NCI-H460 MmC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjmO|IhcA>? NE\5TYVFVVOR MUTJR|UxRThwOUmg{txO MoLCNlM2OjFyMkC=
DLD1 M{LUbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVy3NkBp MU\EUXNQ MVPJR|UxRTRwNjFOwG0> NFjaN4czOzV4N{m2NC=>
NCI-H661 NWj3dXhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYe3NkBp NGL5RmJFVVOR MX3JR|UxRTdwODFOwG0> NID3O5AzOzV4N{m2NC=>
A549 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TEc|czKGh? M4nBOGROW09? M2LFTGlEPTB;OD6yJO69VQ>? MnjsNlM2Pjd7NkC=
U937 NYrBZplXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUG3NkBp MXHEUXNQ MY\JR|UxRTF{LkKg{txO MXKyN|U3Pzl4MB?=
HEK293 M1rzeGZ2dmO2aX;uJGF{e2G7 NULGXXVrOTEEoN88US=> NIO2[olFVVOR NUj1PVdiUW6mdXPld{BjcW6maX7nJIFn\mmwaYT5JJRwKGi3bXHuJIZ2dGxvbHXu[5RpKEircz30ZYdo\WRiTYn0NUBscW6jc3Wg[ZhxemW|c3XkJIlvKEiHS{K5N{Bk\WyuczD3bZRpKEmFNUCgc4YhOC5yNkROwG0> NF;y[nQzOjd5ME[xNC=>
HUVEC MnT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnqe5ExNjF3wrFOwG0> M33vc|czKGh? MljmSG1UVw>? NFrUTmtKdmS3Y3XzJIFvfGmjbnfpc4dmdmmlIHHjeIl3cXS7IHnuJGhWXkWFIHPvMYN2dHS3cnXkJJdqfGhidnHzZ5Vt[XJic33vc5RpKG23c3Ps[UBk\WyuczDhd5Nme3OnZDDhd{BKdmirYnn0bY9vKG:oIHPlcIwh\3Kxd4ToJIF1KDBwMUWgeW0> MVKyNlg2Ozl7Mx?=
HUVEC M1rBTmZ2dmO2aX;uJGF{e2G7 MoLaNVXDqM7:TR?= MVi3NkBp NGDYNodFVVOR M2nvWmlv\HWlZYOgZY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliaX6gTHVXTUNiY3:tZ5VtfHW{ZXSge4l1cCC4YYPjeYxieiC|bX;veIghdXW|Y3zlJINmdGy|IHHzd4V{e2WmIHHzJGlvcGmkaYTpc44hd2ZibnX0e49zcyCob4LtZZRqd25iYYSgNU45KHSxIEG1JJVO M2TTZlIzQDV|OUmz
Plasmodium falciparum NWLNWIZmTnWwY4Tpc44hSXO|YYm= MV[xNOKh|ryP NIL2Xo4yPSCvaX6= MkDvSG1UVw>? M{fKWWlvcGmkaYTzJHBt[XOvb3TpeY0h\mGuY3nwZZJ2dSCycn;sbYZmemG2aX;uJIJ6KGmwaHnibZRqdmdidHjlJGZ2dmO2aX;uJI9nKFCoQ1TQT|EheHKxdHXpckB4cXSqIFnDOVAhd2ZiMT6xO:69VQ>? MW[yOFU2ODN|MB?=
PC3 NFra[4RHfW6ldHnvckBCe3OjeR?= NH[zVlYxNjFizszN M1\p[VUhcA>? Mnv6SG1UVw>? MY\Jcohq[mm2czDoeY1idiCSQ{OgZ4VtdCCjZHjld4lwdiCjdDCxNFAhdk1? M2T2bVE6PDZ{OUe1
DU145 NEnJXJlHfW6ldHnvckBCe3OjeR?= NUWxe5dzOC5zIN88US=> NIfLZZM2KGh? M1GyWWROW09? M2XTVmlvcGmkaYTzJIh2dWGwIFTVNVQ2KGOnbHygZYRp\XOrb36gZZQhOTByIH7N MWWxPVQ3Ojl5NR?=
PC3 MX;LbY5ie2ViQYPzZZk> MlL6NE4yKM7:TR?= Mn;hOUBp NIrLU2hFVVOR NH2yS3NKdmirYnn0d{BkW3KlIHnuJIh2dWGwIGDDN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhW3KlIGm0NVYhdGW4ZXygZZQhOTByIH7N M165V|E6PDZ{OUe1
DU145 NEfKb5RMcW6jc3WgRZN{[Xl? M3j2VVAvOSEQvF2= MW[1JIg> MkW0SG1UVw>? NH;UOmlKdmirYnn0d{BkW3KlIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjDwbI9{eGixconsZZRm\CCVcnOgXVQyPiCuZY\lcEBifCBzMECgcm0> NGiwdGkyQTR4Mkm3OS=>
PC3 MX\LbY5ie2ViQYPzZZk> MljxNE4yKM7:TR?= M1\iVFUhcA>? NE\kZ3hFVVOR MVjJcohq[mm2czDjV5JkKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgSmFMKFl3N{[vXVU4PyCuZY\lcEBifCBzMECgcm0> M4\Vc|E6PDZ{OUe1
DU145 MXHLbY5ie2ViQYPzZZk> M4fOWFAvOSEQvF2= M3naelUhcA>? MX7EUXNQ NV\FfmdNUW6qaXLpeJMh[1O{YzDpckBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gdIhwe3Cqb4L5cIF1\WRiRlHLJHk2PzZxWUW3O{Bt\X[nbDDheEAyODBibl2= M{TOZlE6PDZ{OUe1
Huh7 NHH5dlhCdnSrdnnyZYwhSXO|YYm= NVmx[5ZOOi53IN88US=> NGTt[o81KGSjeYO= M1flfWROW09? NVL2OGxiUW6qaXLpeJMhfmm{YXygd5Bz\WGmIHnuJGRmdme3ZTD2bZJ2ey2rbn\lZ5Rm\CCqdX3hckBJfWh5IHPlcIx{KGG|c3Xzd4VlKGG|IHHjZ5VufWyjdHnvckBw\iC4aYLhcEBmdn[nbH;w[UBxem:2ZXnuJJdqfGirbjDw[ZJqdnWlbHXhdkBz\Werb36gZZQhOi53IIXN M3fORVE4OzZyNke2
C6/36 M3voT2FvfGm4aYLhcEBCe3OjeR?= M4jFUFIvPSEQvF2= NH;IbVY1KGSjeYO= NFPDT|NFVVOR MmXSTY5pcWKrdIOgeolz[Wxic4Dy[YFlKGmwIFTlcod2\SC4aYL1d{1qdm[nY4Tl[EBie2mjbjD0bYdmeiCvb4PxeYl1dyCFNj:zOkBk\WyuczDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25ib3[geolz[WxiZX72[YxweGVicILveIVqdiC5aYTobY4heGW{aX71Z4xm[XJicnXnbY9vKGG2IEKuOUB2VQ>? NGfKfpAyPzN4ME[3Oi=>
U937 MYjGeY5kfGmxbjDBd5NigQ>? MUixJO69VQ>? NF;CSpkyKGh? NUDle2ZJTE2VTx?= MWXS[YR2[2W|IHLhd4FtKFSQRnHsdIhiKHKnbHXhd4UhcW5iaIXtZY4hXTl|NzDj[Yxtew>? MmXDNVc3QDRyOUm=
U937 NFjrTHhHfW6ldHnvckBCe3OjeR?= MY[xJO69VQ>? MUexJIg> M2PHZ2ROW09? NXXueJJrWmWmdXPld{BNWFNvaX7keYNm\CCWTl\hcJBp[SC{ZXzlZZNmKGmwIHj1cYFvKFV7M{egZ4VtdHN? NULzcG5YOTd4OESwPVk>
murine mast cell M3rYXGZ2dmO2aX;uJGF{e2G7 NHrVe|MyKM7:TR?= NUfINHBiOjRiaB?= NETCNlFFVVOR M2DXemlvcGmkaYTzJIFvfGmpZX6tbY5lfWOnZDDJUFYhe2WlcnX0bY9vKGmwIFnnSUBxemmvZXSgcY92e2VibXHzeEBk\WyuczDheEAyKHWP M{XqZVE4Pjh2MEm5
BV-173 MnLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3ETWM2OD1yLkCwNFAxODFyOTFOwG0> M2HvdXNCVkeHUh?=
K-562 NHv0W2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4KxRmlEPTB;MD6wNFAxODB{Nk[g{txO NFy0bHdUSU6JRWK=
BL-70 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUO4Z5BxUUN3ME2wMlAxODByMEiyNkDPxE1? M{TPZnNCVkeHUh?=
EM-2 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTBwMECwNFAyODhizszN NX60bnNnW0GQR1XS
LAMA-84 NEG3c5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnn6TWM2OD1yLkCwNFAxOzJzIN88US=> NWnB[5ozW0GQR1XS
MEG-01 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGi3dY1KSzVyPUCuNFAxODB7ODFOwG0> MnnkV2FPT0WU
EoL-1-cell Mmn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF[xOVFKSzVyPUCuNFAxODF|MTFOwG0> NInhXmVUSU6JRWK=
CTV-1 NXPGdmp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HwTGlEPTB;MD6wNFAxPDB2IN88US=> MmnFV2FPT0WU
TE-15 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjmTWM2OD1yLkCwOVg6KM7:TR?= M4PwUHNCVkeHUh?=
NOS-1 M3jwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PvUmlEPTB;MD6wNFYyOyEQvF2= NWnuUWNLW0GQR1XS
D-336MG M2Dtbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIX3O2xKSzVyPUCuNFA3OyEQvF2= NYLITZZiW0GQR1XS
LB1047-RCC MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTBwMEC5PFkh|ryP NU\wS2cyW0GQR1XS
LB996-RCC NIW5XZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHMWZF2UUN3ME2wMlAxQTlzIN88US=> MnHJV2FPT0WU
SW982 MkXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwMEGxNVUh|ryP NVTJbpY5W0GQR1XS
TK10 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTBwMEGxO|Qh|ryP M37kSXNCVkeHUh?=
A704 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M330O2lEPTB;MD6wNVQ6OSEQvF2= MVXTRW5ITVJ?
TE-8 NXjR[5RJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX62eGl4UUN3ME2wMlAyPTd4IN88US=> MmHzV2FPT0WU
DOHH-2 Ml3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrNcm1KSzVyPUCuNFE4OTlizszN NYXIRoxsW0GQR1XS
HOP-62 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nKWWlEPTB;MD6wNVg{PCEQvF2= MUPTRW5ITVJ?
TE-12 M{ns[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vDR2lEPTB;MD6wNVg3OSEQvF2= M4j0d3NCVkeHUh?=
KGN MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHNZ5B7UUN3ME2wMlAyQTR{IN88US=> MlHrV2FPT0WU
NCI-H1648 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnv5TWM2OD1yLkCyNFEyKM7:TR?= MWjTRW5ITVJ?
OS-RC-2 NGf0cmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmX5TWM2OD1yLkCyNFMh|ryP Moe2V2FPT0WU
GB-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PwUGlEPTB;MD6wNlE2PyEQvF2= MYfTRW5ITVJ?
RXF393 NES3bIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnSwTWM2OD1yLkCyN|U4KM7:TR?= NYHTSoJlW0GQR1XS
LC-2-ad NGKyb5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XXO2lEPTB;MD6wNlU5PiEQvF2= NXWzXYVxW0GQR1XS
KS-1 NXjmSXlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDSZmJTUUN3ME2wMlAzPzNizszN NYrZWFdYW0GQR1XS
ETK-1 Mor4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zBTGlEPTB;MD6wNlg{OiEQvF2= MWjTRW5ITVJ?
SW954 NYfoXJFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPmTWM2OD1yLkCyPVI4KM7:TR?= M4iyUHNCVkeHUh?=
Becker NE\tO3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fBVmlEPTB;MD6wN|AxOyEQvF2= MUPTRW5ITVJ?
MZ1-PC NY\XWnp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLYdWhKSzVyPUCuNFMyOTlizszN NGfRTlZUSU6JRWK=
ES6 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1[2fmlEPTB;MD6wN|E6OyEQvF2= MVzTRW5ITVJ?
KURAMOCHI MonSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1W1ZWlEPTB;MD6wN|Q5PyEQvF2= NGTQT3dUSU6JRWK=
CGTH-W-1 Mm\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3yxPWlEPTB;MD6wN|U1QCEQvF2= NIG1fI1USU6JRWK=
VA-ES-BJ M4LFUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrYNlI2UUN3ME2wMlA{QTB{IN88US=> M4C4XnNCVkeHUh?=
LXF-289 MmnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1T5XGlEPTB;MD6wN|k2PiEQvF2= M1PEPHNCVkeHUh?=
MPP-89 MnX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF36PWFKSzVyPUCuNFQxPDlizszN Mon3V2FPT0WU
SW872 M4LlRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHX0Z3dKSzVyPUCuNFQyPjFizszN MULTRW5ITVJ?
SNB75 NIXmUGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHCOnhKSzVyPUCuNFQ1OzVizszN MmHKV2FPT0WU
PSN1 NHLhU4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1f4W2lEPTB;MD6wOFQ4PCEQvF2= MkfHV2FPT0WU
LB831-BLC NFnoWZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH72[pVKSzVyPUCuNFQ3ODlizszN NHTUU25USU6JRWK=
MFH-ino MnTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTBwMES3NlQh|ryP MWrTRW5ITVJ?
TGBC24TKB MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTBwMES3OlEh|ryP NWe2cJprW0GQR1XS
A388 NFjLOIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTBwMEWwPVUh|ryP MVLTRW5ITVJ?
BB30-HNC MmHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrXXG1KSzVyPUCuNFU1OzdizszN NWPJXphOW0GQR1XS
GI-ME-N MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjOSI9KSzVyPUCuNFYyOThizszN NYr4T5BRW0GQR1XS
TGBC1TKB NWLJSXpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPHRoNYUUN3ME2wMlA3OTZ2IN88US=> NVTXXZFNW0GQR1XS
TE-10 MojwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HydWlEPTB;MD6wOlM2PyEQvF2= MXPTRW5ITVJ?
A498 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nkO2lEPTB;MD6wO|I5PCEQvF2= NVH4cG5JW0GQR1XS
TE-11 M3Loemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIW4fnJKSzVyPUCuNFc5PThizszN M3jhW3NCVkeHUh?=
BB65-RCC NGLKOIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jFcGlEPTB;MD6wPFIzPyEQvF2= M1;qWXNCVkeHUh?=
C2BBe1 MnHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYThXJJ{UUN3ME2wMlA5OzB6IN88US=> MnfHV2FPT0WU
NCI-H747 M1vBSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Lkc2lEPTB;MD6wPFM3OiEQvF2= M2jhOXNCVkeHUh?=
IST-MES1 NGT2[IZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDyTWM2OD1yLkC4OVUzKM7:TR?= NYXxdoJKW0GQR1XS
KALS-1 M2DDcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nSbGlEPTB;MD6wPVQ6KM7:TR?= NVfZUGNjW0GQR1XS
GCIY NF;R[4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jKOWlEPTB;MD6wPVY2PiEQvF2= M1T4NXNCVkeHUh?=
RL95-2 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfzfplFUUN3ME2wMlExOzhizszN NFzwe|FUSU6JRWK=
TE-1 M4nxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\V[mlEPTB;MD6xNFU1KM7:TR?= M{XIRXNCVkeHUh?=
NCI-H1355 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3:xTmlEPTB;MD6xNVAzQCEQvF2= NFy0N|JUSU6JRWK=
SW962 NXrqU5dlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwMUGyPVIh|ryP MoixV2FPT0WU
KLE MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{[xU2lEPTB;MD6xNVMyPyEQvF2= NVPnOZJrW0GQR1XS
MC116 M2PLNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jVOmlEPTB;MD6xNVQyKM7:TR?= MXvTRW5ITVJ?
NMC-G1 NIHIbnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3SzXmlEPTB;MD6xNVYxPiEQvF2= NVnLbHcxW0GQR1XS
KU812 NHHtV5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDiU4hKSzVyPUCuNVE5QDNizszN NIPLPXVUSU6JRWK=
COLO-829 MlTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nkeWlEPTB;MD6xNlIyOyEQvF2= NYHj[FlFW0GQR1XS
NTERA-S-cl-D1 NUXPclVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUftXoVoUUN3ME2wMlEzOjh|IN88US=> NXX3PVZNW0GQR1XS
IST-MEL1 NYjZ[JdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;4WmlEPTB;MD6xN|Q2KM7:TR?= MUTTRW5ITVJ?
MLMA M2S4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHOxPIpKSzVyPUCuNVQxOzJizszN M4DKUnNCVkeHUh?=
LS-123 NUflUWdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwMUSwOlQh|ryP M1fEXnNCVkeHUh?=
LB2518-MEL MkWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYr3[JNqUUN3ME2wMlE1OTZ{IN88US=> MU\TRW5ITVJ?
NB69 NF3VWpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTBwMUS0N|Yh|ryP MYrTRW5ITVJ?
8-MG-BA MmfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NID4Z3FKSzVyPUCuNVU1PThizszN M37IbXNCVkeHUh?=
K5 NV3P[Y1LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrrcWNKSzVyPUCuNVY1QDlizszN M3jnfXNCVkeHUh?=
KINGS-1 NWm3fWZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NISwdmtKSzVyPUCuNVY3PjZizszN MnHzV2FPT0WU
SF268 NWO2cIE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTBwMUe0NFQh|ryP M{fZ[nNCVkeHUh?=
PF-382 NETQWXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjsTWM2OD1yLkG3Olc5KM7:TR?= NU\HXopEW0GQR1XS
SH-4 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX6zSJhFUUN3ME2wMlE5PDF|IN88US=> MVXTRW5ITVJ?
NALM-6 M3qyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTBwMUmyPVUh|ryP NIi0WnhUSU6JRWK=
CP66-MEL MmrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXISIdZUUN3ME2wMlE6PTNzIN88US=> MkHtV2FPT0WU
697 M13vT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLL[nJKSzVyPUCuNVk6QDdizszN MXHTRW5ITVJ?
CP67-MEL MojpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;jbGlEPTB;MD6yNFQ5QCEQvF2= M{XTVnNCVkeHUh?=
DSH1 NF\vR3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{f6RmlEPTB;MD6yOFAxOSEQvF2= MW\TRW5ITVJ?
HCE-4 M1r5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTBwMk[0N|kh|ryP NFHJOWpUSU6JRWK=
MZ2-MEL NUnlPJNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2npS2lEPTB;MD6yPFU{PyEQvF2= NH3NPY5USU6JRWK=
BL-41 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnN[JRmUUN3ME2wMlI6OTJ|IN88US=> MoWzV2FPT0WU
HUTU-80 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\xc5doUUN3ME2wMlMyPDJizszN MUnTRW5ITVJ?
LOXIMVI MlL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnDTWM2OD1yLkOxOVA{KM7:TR?= NFTMdGRUSU6JRWK=
no-10 NH3kdpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFT1SVZKSzVyPUCuN|E6OzFizszN MoLHV2FPT0WU
KARPAS-422 NX;oUYltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2OyXmlEPTB;MD6zN|k6PyEQvF2= NIXLNJVUSU6JRWK=
SW684 MmL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HSNmlEPTB;MD6zOFk5KM7:TR?= M1XOenNCVkeHUh?=
SF126 NHjtPJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7RcFhKSzVyPUCuN|U1OSEQvF2= NGTEZ2tUSU6JRWK=
D-263MG M2LPOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NICwVWZKSzVyPUCuN|YzOjRizszN NHXKT4lUSU6JRWK=
OVCAR-4 MoP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFn2[YdKSzVyPUCuN|c1OzNizszN MnnVV2FPT0WU
BB49-HNC M1L4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTBwM{i1PVkh|ryP NUfMNHNIW0GQR1XS
ONS-76 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwNEK5OVEh|ryP NWHSTWlFW0GQR1XS
MZ7-mel M2HlU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzkdpRQUUN3ME2wMlQ4QTFzIN88US=> Mk\6V2FPT0WU
RCC10RGB NH\FOFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXvTWM2OD1yLkS5NVEh|ryP NGi4TJZUSU6JRWK=
BOKU MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TTcGlEPTB;MD60PVE{OyEQvF2= NXfnbFhZW0GQR1XS
no-11 MmnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWm5XZNSUUN3ME2wMlUxOjJ6IN88US=> MULTRW5ITVJ?
IST-SL2 NXnn[2RpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLOVW1KSzVyPUCuOVA{ODJizszN NVnsXGxUW0GQR1XS
RKO Moj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTBwNUK5OlYh|ryP M2XwV3NCVkeHUh?=
HT-144 NESwZ2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4j0RWlEPTB;MD61N|YxQSEQvF2= NIDuTmtUSU6JRWK=
NCI-H446 M2nYN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3S0fWlEPTB;MD62Nlc3KM7:TR?= NEW5N4ZUSU6JRWK=
QIMR-WIL NHnoWG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjBTWM2OD1yLkewOlI6KM7:TR?= NFfNZnJUSU6JRWK=
MHH-PREB-1 NXezOVlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;lS4xpUUN3ME2wMlc1PDZ7IN88US=> M4LrTHNCVkeHUh?=
EW-16 M2DwOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDmeJhKSzVyPUCuO|YyPzhizszN NH:3WmlUSU6JRWK=
EW-24 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLOTWM2OD1yLke4NVY2KM7:TR?= MmXFV2FPT0WU
LB373-MEL-D NVvqRW1uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TJXmlEPTB;MD64NlUxQCEQvF2= NYrmT3pIW0GQR1XS
TE-9 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFO2fldKSzVyPUCuPFc2OzJizszN NXjUXnJmW0GQR1XS
A3-KAW NHrzfWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPMTWM2OD1yLkm4OFUzKM7:TR?= MXnTRW5ITVJ?
A101D NXO5[HJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TmeWlEPTB;MT6wN|A1OyEQvF2= Moj4V2FPT0WU
OCUB-M MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVy4XoVbUUN3ME2xMlA1PDF{IN88US=> NWDxVmJCW0GQR1XS
ES4 NGDSVGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{niW2lEPTB;MT6wOVE1PSEQvF2= MljUV2FPT0WU
TE-6 NU\NcXJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTyTWM2OD1zLkKxNlI3KM7:TR?= NYCzV5VwW0GQR1XS
D-502MG NEXMS3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDyV2dyUUN3ME2xMlI{Ozd4IN88US=> MVrTRW5ITVJ?
KNS-42 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLLTWM2OD1zLkK0OFEzKM7:TR?= Mkj2V2FPT0WU
SNU-C2B MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDmTWM2OD1zLkOwOVg6KM7:TR?= NIrFVlNUSU6JRWK=
NCI-H1838 M4nMWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nud2lEPTB;MT6zNFc{OyEQvF2= Mny0V2FPT0WU
NKM-1 M1vtOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3kUItKSzVyPUGuN|A5PTlizszN MWnTRW5ITVJ?
GI-1 NIPyfG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXVZYlKSzVyPUGuN|YzOiEQvF2= MVvTRW5ITVJ?
NB5 MnjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4G3e2lEPTB;MT6zPVgzPyEQvF2= MXnTRW5ITVJ?
CAS-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPV[4dIUUN3ME2xMlQxQTl{IN88US=> NWC0T4REW0GQR1XS
HCE-T MmfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rPR2lEPTB;MT61OlcyPCEQvF2= NYHxbJo5W0GQR1XS
SBC-1 M1TlUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4K3eWlEPTB;MT61O|k5PCEQvF2= MVTTRW5ITVJ?
JiyoyeP-2003 MlvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PKU2lEPTB;MT63N|Q3PiEQvF2= MV7TRW5ITVJ?
TE-5 MlixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PkTGlEPTB;MT63PVE{QSEQvF2= MoX2V2FPT0WU
CAN M4PabGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTFwOEKyOVIh|ryP MVzTRW5ITVJ?
SK-UT-1 M2\sbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLFTWM2OD1{LkG2Olk{KM7:TR?= M333bHNCVkeHUh?=
JVM-2 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXFOWJsUUN3ME2yMlM3Ojh2IN88US=> MkXoV2FPT0WU
LB771-HNC MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWriOVlJUUN3ME2yMlU4PTVzIN88US=> MVnTRW5ITVJ?
NCCIT NI\ad5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfpc25KSzVyPUKuPFY3OTZizszN NWflUm4zW0GQR1XS
NCI-H2126 NYPsRWI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPrcWJiUUN3ME2yMlg4PTV{IN88US=> NVfj[XdoW0GQR1XS
Calu-6 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXaeINKSzVyPUOuNFU4PDFizszN NIDJWGZUSU6JRWK=
SK-LMS-1 NIP3fXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXQXZhKSzVyPUOuNVE5QDZizszN MnPFV2FPT0WU
ARH-77 M1\GZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jreGlEPTB;Mz60OlkyPSEQvF2= M{XTfXNCVkeHUh?=
NB17 M1j3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XreWlEPTB;Mz62N|g1PyEQvF2= NYDnS441W0GQR1XS
A253 NGTtRpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7ITWM2OD1|LkezNlQ3KM7:TR?= M3zHXnNCVkeHUh?=
OPM-2 NUS1fWlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fXUGlEPTB;ND6yO|Y5PSEQvF2= Mk\iV2FPT0WU
MV-4-11 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTXN2RKSzVyPUSuN|Y1PTRizszN NGC4dlVUSU6JRWK=
SR MnnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorOTWM2OD12LkS5PVU1KM7:TR?= NUjTbFVpW0GQR1XS
KG-1 M{L2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrFO5l1UUN3ME20MlYxQDR3IN88US=> Moq1V2FPT0WU
OCI-AML2 M2L4cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHOTWM2OD13Lki2NVU1KM7:TR?= MkToV2FPT0WU
D-247MG Moi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\JTWM2OD14LkGyOVE6KM7:TR?= NGLpbFVUSU6JRWK=
DJM-1 NFy1e4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILXTWlKSzVyPU[uOFg2PThizszN NV60b|V[W0GQR1XS
RPMI-6666 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDNVmVlUUN3ME23MlI4ODZ5IN88US=> M1zoVXNCVkeHUh?=
KARPAS-45 MnL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jtfGlEPTB;Nz61NVY4OSEQvF2= MYfTRW5ITVJ?
LP-1 NYLYSIZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUf4NI56UUN3ME23MlU1Pzh{IN88US=> M3G1ZXNCVkeHUh?=
RS4-11 NF\YcFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LoPWlEPTB;Nz62OVc5PyEQvF2= MonmV2FPT0WU
DU-4475 NUfqTmx2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXrTWM2OD16LkKxOlUzKM7:TR?= MWHTRW5ITVJ?
MONO-MAC-6 NWn4OJhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;UdmFKSzVyPUiuNlcxPjZizszN MmD0V2FPT0WU
NCI-SNU-16 NXSxXYNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRThwNU[xNlgh|ryP MmDGV2FPT0WU
SJSA-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XjNWlEPTB;OD63NlgxPSEQvF2= MoLBV2FPT0WU
MMAC-SF NFfZ[GtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvkeI96UUN3ME24Mlc6OzB5IN88US=> NFjSe3VUSU6JRWK=
SK-NEP-1 M3z6bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHjOG9OUUN3ME24Mlg6OTV3IN88US=> NV3NOnBTW0GQR1XS
J-RT3-T3-5 Mlr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PEXGlEPTB;OD65OlUzQSEQvF2= NGDnT3FUSU6JRWK=
SKM-1 NGf4WGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;teoQyUUN3ME25MlAyPzN2IN88US=> M{DOW3NCVkeHUh?=
LB2241-RCC MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fZT2lEPTB;OT6wNlAyOiEQvF2= M37COHNCVkeHUh?=
SIG-M5 M{XMd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWC5WohmUUN3ME25MlAzPDl|IN88US=> M1L5cXNCVkeHUh?=
EVSA-T M37DfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTlwMke3PVMh|ryP NVz3XG5zW0GQR1XS
GT3TKB MnTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVniWnZKUUN3ME25MlM2PTR4IN88US=> Mlf4V2FPT0WU
NB6 M{ezUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfBeldKSzVyPUmuPVIzPTlizszN NX\vTWpoW0GQR1XS
EHEB MlHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfudlN1UUN3ME2xNE4xPjV4IN88US=> M3Gy[nNCVkeHUh?=
HEL MneyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTFyLkS3O|Yh|ryP MYLTRW5ITVJ?
ALL-PO M4nrO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFKxUIJKSzVyPUGwMlc6OzhizszN M1jN[3NCVkeHUh?=
TGW MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTHTWM2OD1zMT6yPFI5KM7:TR?= M32wNnNCVkeHUh?=
BC-3 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;KVHlKSzVyPUGyMlEyOzhizszN NInvdFdUSU6JRWK=
IA-LM NH6zbWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXhdYI4UUN3ME2xNk41PDR3IN88US=> M3y3SHNCVkeHUh?=
UACC-257 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTF{LkmxPVgh|ryP M4DNcnNCVkeHUh?=
KP-N-YS Mm\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jldWlEPTB;MUKuPVI5OyEQvF2= MXfTRW5ITVJ?
Raji NUjKdmpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTF|Lke0PVch|ryP NXzBeXhVW0GQR1XS
SF539 MmT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml24TWM2OD1zMz64OVU4KM7:TR?= M1rPT3NCVkeHUh?=
DMS-153 Mli1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXzTWM2OD1zND6wNFI5KM7:TR?= M4jMPHNCVkeHUh?=
L-540 M{XDSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTF3LkC2O|Ih|ryP NW\G[oQyW0GQR1XS
MN-60 NXX4Vm9XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3r2RmlEPTB;MUWuNVk4QSEQvF2= M4LoNHNCVkeHUh?=
RPMI-8866 Ml;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDJTWM2OD1zNz60OFU1KM7:TR?= MofFV2FPT0WU
NCI-H510A MnzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;JXnFqUUN3ME2xPU4{QTd|IN88US=> M1n3XHNCVkeHUh?=
NB13 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVT6c|BqUUN3ME2xPU41QDd5IN88US=> Mk\zV2FPT0WU
HAL-01 MoXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmD1TWM2OD1zOT63OVQ{KM7:TR?= NIe1VXZUSU6JRWK=
NCI-H720 NYLxN2hsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDPPWVKSzVyPUKwMlI4OzNizszN NV7RPYdJW0GQR1XS
REH MnLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jpTGlEPTB;MkCuOlM2PyEQvF2= MWjTRW5ITVJ?
KNS-81-FD NX;NVXNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTJ|LkG0OkDPxE1? M1\SZnNCVkeHUh?=
HC-1 Mn;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH6yO|NKSzVyPUK0MlU2PTFizszN NIjQW4tUSU6JRWK=
NCI-H2141 NV3NRmJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXPRnFtUUN3ME2yOE44PzV2IN88US=> NHv6dnZUSU6JRWK=
MOLT-4 NXPNVpRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1r2c2lEPTB;Mk[uOlc2OyEQvF2= MkW5V2FPT0WU
OMC-1 NWXZVmFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTJ5LkG0NlIh|ryP Mln4V2FPT0WU
LC-1F NWfXSY9pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\VUHhMUUN3ME2yO{4{OjR3IN88US=> NIDkV5NUSU6JRWK=
NCI-H1304 M4e1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnLWm15UUN3ME2yPE4yPjJ6IN88US=> MkPxV2FPT0WU
BC-1 MoSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPzXVdKSzVyPUK4MlY2OSEQvF2= NF64PJlUSU6JRWK=
NCI-H64 M{H6bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXu5V|U{UUN3ME2yPU43OjV|IN88US=> MVLTRW5ITVJ?
MOLT-16 Mk\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\CTWM2OD1{OT62NlkzKM7:TR?= M{LITXNCVkeHUh?=
U-87-MG NYDtRXo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlGzTWM2OD1|MD63OlYh|ryP MYHTRW5ITVJ?
GAK M2DYPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEm3UoZKSzVyPUOxMlI3QDZizszN M1HYd3NCVkeHUh?=
ES8 M1La[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTN{LkGyOVIh|ryP MX;TRW5ITVJ?
HCC1599 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmP1TWM2OD1|Mj6zN|I2KM7:TR?= NWPa[5A{W0GQR1XS
EB-3 NECwcmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkS2TWM2OD1|ND6zNVE4KM7:TR?= MnjzV2FPT0WU
HCC1187 NIr1XZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HoemlEPTB;M{WuPFA2OiEQvF2= NF3weFRUSU6JRWK=
SK-PN-DW NY[3O4c1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTN4LkG5OFMh|ryP NHXuVphUSU6JRWK=
JVM-3 NWm1TpA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDiVFdKSzVyPUO3MlI{OzhizszN M2TQbXNCVkeHUh?=
HCC2157 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPDfGplUUN3ME2zO{46QTR4IN88US=> M33QO3NCVkeHUh?=
A4-Fuk NGfOTGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoW1TWM2OD1|OD6xNFA6KM7:TR?= NEO5PVhUSU6JRWK=
COR-L279 NHH2ZnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXWeoVKSzVyPUSwMlI5PTFizszN NYPkSYtPW0GQR1XS
DEL NH3leHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUW4TJRLUUN3ME20NU46ODh4IN88US=> MVLTRW5ITVJ?
NCI-H1395 NXrqWnZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\BWmRKSzVyPUSyMlAyPjNizszN NHjRVZBUSU6JRWK=
MHH-NB-11 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHOSFhKSzVyPUSzMlA5OThizszN NYfzTo9MW0GQR1XS
NCI-H2107 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTDTWM2OD12Mz60PFQ3KM7:TR?= MlTXV2FPT0WU
NEC8 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXJfFRKSzVyPUS0MlM{PiEQvF2= MoDzV2FPT0WU
COLO-684 M2rwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\5W|RKSzVyPUS2MlIzPThizszN M3;mPHNCVkeHUh?=
LS-411N MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3FOG5KSzVyPUS4MlQ4PDhizszN NEntfY1USU6JRWK=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Kinase autophosphorylation assays:

Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
細胞試験:

[1]

+ 展開
  • 細胞株: Ba/F3 cell lines
  • 濃度: ~32 nM
  • 反応時間: 72 hours
  • 実験の流れ:

    Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.


    (参考用のみ)
動物試験:

[3]

+ 展開
  • 動物モデル: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
  • 製剤: DMSO
  • 投薬量: 30 mg/kg
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 98 mg/mL (200.81 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 488.01
化学式

C22H26ClN7O2S

CAS No. 302962-49-8
保管
in solvent
別名 BMS-354825

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03318770 Not yet recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dell''Adulto December 2018 --
NCT03625388 Not yet recruiting Chronic Myelogenous Leukemia Hikma Pharmaceuticals LLC October 2018 Phase 2
NCT03516279 Not yet recruiting Chronic Phase Chronic Myelogenous Leukemia BCR-ABL1 Positive|Minimal Residual Disease ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group August 12 2018 Phase 2
NCT03595917 Recruiting B-cell Acute Lymphoblastic Leukemia|Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis|Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL Marlise R. Luskin|Novartis|Dana-Farber Cancer Institute July 24 2018 Phase 1
NCT03654768 Recruiting Chronic Phase Chronic Myelogenous Leukemia BCR-ABL1 Positive Southwest Oncology Group|National Cancer Institute (NCI) July 20 2018 Phase 2
NCT03560908 Recruiting Relapsed AML|T(8;21)|C-KIT Mutation Institute of Hematology & Blood Diseases Hospital July 1 2018 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    what’s the difference between S1021 and S7782? Which one is better for in vivo studies?

  • 回答:

    Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).

  • 質問2:

    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

  • 回答:

    Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Srcシグナル伝達経路

Src Inhibitors with Unique Features

相関Src製品

Tags: Dasatinibを買う | Dasatinib ic50 | Dasatinib供給者 | Dasatinibを購入する | Dasatinib費用 | Dasatinib生産者 | オーダーDasatinib | Dasatinib化学構造 | Dasatinib分子量 | Dasatinib代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID